FibroBiologics Inc. Announces Multiple Share Transactions: Conversion of Notes Results in Issuance of Over 2.15 Million Shares

Reuters
19 Jul
<a href="https://laohu8.com/S/FBLG">FibroBiologics</a> Inc. Announces Multiple Share Transactions: Conversion of Notes Results in Issuance of Over 2.15 Million Shares

FibroBiologics Inc. conducted several share transactions with YA II PN, Ltd., a Cayman Islands exempt limited company, as part of a Standby Equity Purchase Agreement. On June 20, 2025, the Investor converted $100,000 of the Second Note into 144,216 shares at $0.6934 per share. On June 24, 2025, $200,000 was converted into 295,377 shares at $0.6771 per share. On June 26, 2025, $300,000 of the Third Note was converted into 443,066 shares at $0.6771 per share. On June 27, 2025, $500,000 was converted into 738,443 shares at $0.6771 per share. Finally, on July 15, 2025, $300,000 was converted into 533,428 shares at $0.5624 per share.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fibrobiologics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000950170-25-096914), on July 18, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10